PepCan for Head and Neck Cancer
Trial Summary
What is the purpose of this trial?
This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of HPV-related malignancies starting from infection to cancer. Safety, efficacy in terms of reduced cancer recurrence, immunological responses and profiles, and gut microbiome changes will be assessed.
Research Team
Omar T Atiq, MD
Principal Investigator
University of Arkansas
Eligibility Criteria
Adults over 18 who've had squamous cell carcinoma of the head and neck, are now in remission after curative therapy, and have a stable health status (specific vital signs and blood counts). Excluded are those with severe recent asthma issues, past cancer recurrence, pregnant or breastfeeding women, yeast allergy sufferers, or previous PepCan recipients.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a total of 7 injections of PepCan or placebo over a 24-month period
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PepCan
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Arkansas
Lead Sponsor